Allogene Therapeutics
Logotype for Allogene Therapeutics Inc

Allogene Therapeutics (ALLO) investor relations material

Next Allogene Therapeutics earnings date

Logotype for Allogene Therapeutics Inc
38th Annual Healthcare Conference2 Dec, 2026
Allogene Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Allogene Therapeutics earnings date

Logotype for Allogene Therapeutics Inc
38th Annual Healthcare Conference2 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Allogene Therapeutics Inc is a biotechnology company focused on developing allogeneic CAR T cell therapies for cancer treatment. The company’s approach uses gene-editing and cell engineering technologies to produce off-the-shelf immunotherapies designed to target various hematologic and solid tumors. Its operations span research, clinical trials, and manufacturing. Allogene Therapeutics Inc is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.